Cortical amino acidergic pathways in Alzheimer's disease
In Frontiers in Neuroanatomy, 1986
... (VGLUT-1, 1:5,000, AB5905: Chemicon); parvalbumin (PV, 1:1,000, AB11427: Abcam, Cambridge, United Kingdom); and an anti-human PHF-tau monoclonal antibody (clone AT8, 1:100, MN1020: Thermo Scientific; Waltham, MA, USA) ...
Cellular and molecular modifier pathways in tauopathies: the big picture from screening invertebrate models.
Heidelberg, Germany. In J Neurochem, 12 Feb 2016
UNASSIGNED: Abnormal tau accumulations were observed and documented in postmortem brains of patients affected by Alzheimer's disease (AD) long before the identification of mutations in the Microtubule associated protein tau (MAPT) gene, encoding the tau protein, in a different neurodegenerative disease called Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17).
Genome-wide Meta-analysis on the Sense of Smell Among US Older Adults.
New Caledonia. In Medicine (baltimore), Nov 2015
(rs199443 in NSF, P = 3.02 × 10; and rs2732614 in KIAA1267-LRRC37A, P = 6.65 × 10) exhibited cis effects on the expression of microtubule-associated protein tau (MAPT, 17q21.31) in 447 frontal-cortex samples obtained postmortem and profiled by RNA-seq (P < 1 × 10).
Genetics of dementia.
Sydney, Australia. In Lancet, 2014
In this Review, we focus on the evidence for, and the approach to, genetic testing in Alzheimer's disease (APP, PSEN1, and PSEN2 genes), frontotemporal dementia (MAPT, GRN, C9ORF72, and other genes), and other familial dementias.
Tau pathology and neurodegeneration.
Cambridge, United Kingdom. In Lancet Neurol, 2013
The pathway leading from soluble and monomeric to hyperphosphorylated, insoluble and filamentous tau protein is at the centre of many human neurodegenerative diseases, collectively referred to as tauopathies.